Tempus AI, Inc. (TEM) · Oct 23, 2026 · Material agreement

Tempus AI signs $192.5M BMS data agreement over five years

$192.5M data agreement — BMS $137.5M fixed plus Pathos up to $55M over approximately five years

Tempus AI expands its BMS and Pathos data agreements to $192.5 million, strengthening pharma demand while spreading payments and delivery risk over five years.

Tempus is building a higher-growth data and applications business alongside its diagnostics operation, with recent momentum coming from oncology data licensing and AI tools for drug development; in Q2, the company said Data Licensing & Modeling revenue rose 36% year over year and that it had signed roughly $200 million of new Data and Applications licenses.

The filing converts that strategy into a large, multi-year commercial commitment. The BMS oncology agreement adds de-identified multimodal records, Lens software access, and research services, while the Pathos agreement extends Tempus’s data and agentic analysis tools into neurology and BMS’s therapeutic-development work. The two agreements together provide for $192.5 million of cash payments over approximately five years.

AgreementCustomer structureEconomicsTiming / delivery
Onco SOWBMS$137.5M fixed paymentsQuarterly through December 31, 2031
Neuro Order FormPathos, with sublicense rights to BMSUp to $55M: $50M for delivered records plus $5M for updates500,000 neurology records over five years

The quality of the revenue is better than a one-off data sale, but it is not $192.5 million of near-term revenue. The BMS oncology payments are fixed and invoiced quarterly, providing visibility. The neurology component is conditional on Tempus delivering the records, so its $55 million ceiling is not guaranteed. 〔0〕

The main tradeoff is limited exclusivity around the neurology data. Tempus cannot license the applicable records to third parties during the specified protection period, which may restrict near-term reuse of some data even as the BMS relationship validates demand for Tempus’s multimodal datasets and agentic tools. The Pathos transactions were also reviewed by a special committee because of related-party overlap, reducing the governance ambiguity but not changing the economics.

Bottom line: This is a meaningful expansion of Tempus’s pharma-data commercialization story and adds substantial contracted demand beyond diagnostics. It matters positively, but the financial impact builds gradually and depends partly on execution and record delivery rather than arriving upfront.

Original filing on SEC EDGAR

Tempus AI signs $192.5M BMS data agreement over five years | TEM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.